- Home
- RCS vs TNXP Comparison
RCS vs TNXP Comparison
Compare RCS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- TNXP
- Stock Information
- Founded
- RCS 1994
- TNXP 2007
- Country
- RCS United States
- TNXP United States
- Employees
- RCS N/A
- TNXP N/A
- Industry
- RCS Investment Managers
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- TNXP Health Care
- Exchange
- RCS Nasdaq
- TNXP Nasdaq
- Market Cap
- RCS 329.4M
- TNXP 335.6M
- IPO Year
- RCS N/A
- TNXP N/A
- Fundamental
- Price
- RCS $7.13
- TNXP $51.35
- Analyst Decision
- RCS
- TNXP Buy
- Analyst Count
- RCS 0
- TNXP 1
- Target Price
- RCS N/A
- TNXP $70.00
- AVG Volume (30 Days)
- RCS 141.1K
- TNXP 1.8M
- Earning Date
- RCS 01-01-0001
- TNXP 08-11-2025
- Dividend Yield
- RCS 10.12%
- TNXP N/A
- EPS Growth
- RCS N/A
- TNXP N/A
- EPS
- RCS N/A
- TNXP N/A
- Revenue
- RCS N/A
- TNXP $9,831,000.00
- Revenue This Year
- RCS N/A
- TNXP $22.87
- Revenue Next Year
- RCS N/A
- TNXP $711.66
- P/E Ratio
- RCS N/A
- TNXP N/A
- Revenue Growth
- RCS N/A
- TNXP N/A
- 52 Week Low
- RCS $4.51
- TNXP $6.76
- 52 Week High
- RCS $6.31
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- RCS 57.05
- TNXP 55.76
- Support Level
- RCS $7.05
- TNXP $42.12
- Resistance Level
- RCS $7.22
- TNXP $69.97
- Average True Range (ATR)
- RCS 0.07
- TNXP 6.06
- MACD
- RCS -0.01
- TNXP 1.01
- Stochastic Oscillator
- RCS 48.89
- TNXP 45.73
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.